APLS Stock Recent News

Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.

Apellis Pharmaceuticals, Inc. (APLS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT.

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares fell more than 22% after it said it expects European regulators to reject its therapeutic intravitreal pegcetacoplan for the eye disease geographic atrophy (GA), an advanced form of age-related macular degeneration that is a leading cause of blindness.   The stock was down 22.8% at US$48.51 in the late morning on Thursday.

Apellis Pharmaceuticals Inc.'s stock APLS, +1.81% tumbled 14% early Thursday, after the company said it's been informed of a negative trend vote on the European marketing authorization application (MAA) for its treatment for an advanced form of age-related macular degeneration that's a leading cause of blindness. The company said it had an oral explanation meeting with the Europe Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 13 regarding its MAA for pegcetacoplan as a treatment for geographic atrophy, or GA, and was then informed of the negative trend vote.

Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - CCO Caroline Baumal - CMO Meredith Kaya - SVP, IR Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Derek Archila - Wells Fargo Eliana Merle - UBS Akash Tewari - Jefferies Annabel Samimy - Stifel Financial Corp. Douglas Tsao - H.C. Wainwright Joseph Stringer - Needham & Company Operator Good morning ladies and gentlemen.